Optimal Pressure Regulation of the Pneumatic Ventricular Assist Device With Bellows‐Type Driver

Lee, Jung Joo; Kim, Bum Soo; Choi, Jaesoon; Choi, Hyuk; Ahn, Chi Bum; Nam, Kyoung Won; Jeong, Gi Seok; Lim, Choon Hak; Son, Ho Sung; Sun, Kyung

doi:10.1111/j.1525-1594.2009.00780.x

Cited by 4 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since their initial development, most pneumatic ventricular assist devices (VADs) have had large, heavy air compressors, which can limit the mobility of patients.Therefore, many groups have tried to make a compact driver (1)(2)(3)(4).The authors developed paracorporeal pulsatile pneumatic biventricular assist devices (bi-VADs) with a portable driver. The paracorporeal pulsatile pneumaticVAD is illustrated in Fig.1 and has been previously reported (5).…”

mentioning

confidence: 62%

“…This VAD driver has a small volume that is suitable for portable devices. The optimal pneumatic pressure conditions according to various afterload conditions aiming for optimal flow rates were investigated, and an afterload estimation algorithm was investigated (5).…”

Section: Discussionmentioning

confidence: 99%

“…Moderate: occasional failures One occurrence every three months or three occurrences in 1000 events. 5 One occurrence every six months to one year or one occurrence in 10 000 events. 4 One occurrence per year or six occurrences in 100 000 events.…”

Section: Appendix A: Detection Rating Scale For Failure Mode Effect Amentioning

confidence: 99%

“…The paracorporeal pulsatile pneumaticVAD is illustrated in Fig.1 and has been previously reported (5).…”

mentioning

confidence: 96%

See 3 more Smart Citations

A Durability Study of a Paracorporeal Pulsatile Electro‐Mechanical Pneumatic Biventricular Assist Device

et al. 2011

Self Cite

View full text Add to dashboard Cite

In 2002, the paracorporeal pulsatile electro-mechanical pneumatic ventricular assist device (VAD) began to be developed by the Korea Artificial Organ Center at Korea University under a Health & Medical Technology Research and Development program which finished in 2008. In vitro durability testing was conducted on the paracorporeal pulsatile pneumatic VAD to determine device durability and to evaluate device failures. The 1- and 2-year reliability of the paracorporeal pulsatile pneumatic VAD was shown to be 91.2% and 54.9%, respectively, with an 80% confidence level. Failure modes were analyzed using fault tree analysis, with customized software continuously acquiring data during the test period. After this period, 21 in vivo animal tests were done, with 14 cases of left atrium to left ventricle (LV) inflow cannulation (36Fr)/outflow grafting to descending aorta, and seven cases of apex cannulation of LV to descending aorta (12 mm). The longest postoperative day (182 days) in Korea was recently recorded in in vivo animal testing (bovine, 90 kg, male, 3.5-4.0 L/min flow rate, and 55 bpm).

show abstract

mentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Appendix A: Detection Rating Scale For Failure Mode Effect Amentioning

confidence: 99%

“…The paracorporeal pulsatile pneumaticVAD is illustrated in Fig.1 and has been previously reported (5).…”

mentioning

confidence: 96%

See 2 more Smart Citations

A Durability Study of a Paracorporeal Pulsatile Electro‐Mechanical Pneumatic Biventricular Assist Device

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Jung Joo Lee et al. (35) of the Korea Artificial Organ Center, Seoul, Korea reported on the regulation of the bellows‐type pneumatic VAD. This device generates pneumatic pressure with compression of bellows instead of using air and is suitable for portable devices.…”

Section: Cardiac Support and Blood Pumpsmentioning

confidence: 99%

Artificial Organs 2009: A Year in Review

Malchesky¹

2010

Artificial Organs

View full text Add to dashboard Cite

In this editor's review, all articles published in 2009 are organized by category and briefly summarized. As Artificial Organs continues in the original mission of its founders "to foster communications in the field of artificial organs on an international level," we strive to publish the very best developments and clinical applications of artificial organ technologies in this broad and expanding field. In this editor's review, we aim to provide a reflection of the currently available worldwide knowledge that is intended to advance and improve human life while providing insight for continued application of technologies and methods of organ replacement, recovery, and regeneration. APHERESISClaudia Stefanutti et al. (1) of the University of Rome, Rome, Italy studied lowering lipoprotein Lp(a) using a reusable low density lipoprotein (LDL)-adsorber that allowed the removal of both LDL and Lp(a) from plasma. Two male patients with hyper-Lp(a) lipoproteinemia, without elevation of LDL-cholesterol, who had not responded to diet and medication were submitted to 50 LDL Lp(a) aphereses at weekly and biweekly intervals. Total cholesterol, LDL cholesterol, triglycerides, and Lp(a) plasma levels fell significantly. High density lipoprotein (HDL) cholesterol concentrations in plasma did not show a statistically significant change. Clinically, all sessions were well tolerated and no undesired reactions were reported. The adsorber's reusability for several sessions was confirmed.Claudia Stefanutti et al.(2) also reported on a multicenter study of therapeutic exchange (TPE) in patients with severe hypertriglyceridemia (sHTG). Seventeen patients who had not responded to conventional medical therapy (fat-free diet plus pharmaceutical interventions) were referred for TPE. Two hundred and seventeen TPE sessions were performed, and therapy is ongoing for 29.4% of the patients. After treatment, the mean plasma TG and total cholesterol concentrations were significantly reduced. The removal of triglyceride-richlipoproteins prevented relapses of acute pancreatitis. TPE provides a therapeutic option for preventing life-threatening sHTG. BLOOD SUBSTITUTESSabura Neya et al.(3) of Chiba University, Inage-Yayoi, Chiba, Japan evaluated the biological function of the core modified porphyrin isomers such as porphycene, corrphycene, and hemiporphycene. The iron complexes stoichiometrically coupled with apomyoglobin afford stable holoproteins. The oxygen affinity of the reconstituted myoglobins (Mb) changed over a 60 000-fold range depending on the

show abstract

Testing of Safety-Critical Software Embedded in an Artificial Heart

Deok¹,

Jeong²,

Yoo

et al. 2010

Advances in Systems Safety

View full text Add to dashboard Cite

Software is being used more frequently to control medical devices such as artificial heart or robotic surgery system. While much of software safety issues in such systems are similar to other safety-critical systems (e.g., nuclear power plants), domain-specific properties may warrant development of customized techniques to demonstrate fitness of the system on patients. In this paper, we report results of a preliminary analysis done on software controlling a Hybrid Ventricular Assist Device (H-VAD) developed by Korea Artificial Organ Centre (KAOC). It is a state-of-the-art artificial heart which completed animal testing phase. We performed software testing in in-vitro experiments and animal experiments. An abnormal behaviour, never detected during extensive in-vitro analysis and animal testing, was found.

show abstract

Optimal Pressure Regulation of the Pneumatic Ventricular Assist Device With Bellows‐Type Driver

Cited by 4 publications

References 15 publications

A Durability Study of a Paracorporeal Pulsatile Electro‐Mechanical Pneumatic Biventricular Assist Device

A Durability Study of a Paracorporeal Pulsatile Electro‐Mechanical Pneumatic Biventricular Assist Device

Artificial Organs 2009: A Year in Review

Testing of Safety-Critical Software Embedded in an Artificial Heart

Contact Info

Product

Resources

About